Carmustine
Carmustine Brand names, Carmustine Analogs
Carmustine Brand Names Mixture
- No information avaliable
Carmustine Chemical_Formula
C5H9Cl2N3O2
Carmustine RX_link
http://www.rxlist.com/cgi/generic3/carmustine.htm
Carmustine fda sheet
Carmustine msds (material safety sheet)
Carmustine Synthesis Reference
Johnston TP et al. J Med Chem 122:669-681(1963).
Carmustine Molecular Weight
214.049 g/mol
Carmustine Melting Point
31 oC
Carmustine H2O Solubility
< 0.1 g/100 mL at 18 °C
Carmustine State
Solid
Carmustine LogP
1.256
Carmustine Dosage Forms
Powder for solution; Wafer
Carmustine Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Carmustine Pharmacology
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Carmustine Absorption
5 to 28% bioavailability
Carmustine side effects and Toxicity
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
Carmustine Patient Information
No information avaliable
Carmustine Organisms Affected
Humans and other mammals
